OSTX

OS THERAPIES INCORPORATED

• Newsfile·4d ago

  OS Therapies Appoints Craig Eagle, MD as Strategic Advisor

• Dow Jones·4d ago

  OS Therapies Is Maintained at Buy by D. Boral Capital

• TipRanks·04/02 22:40

  OS Therapies bolsters funding to advance OST-HER2 program

• Newsfile·04/02 21:15

  OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors

• TipRanks·04/01 16:35

  Regulatory Momentum and De-Risked Path to Accelerated Approval Support Buy Rating on OST-HER2 Osteosarcoma Program

• TipRanks·04/01 12:42

  OS Therapies price target lowered to $14 from $17 at Lake Street

• TipRanks·04/01 00:07

  OS Therapies Files Prospectus Supplement for Share Resale

• Benzinga·03/31 11:54

  OS Therapies Q4 EPS $(0.41) Misses $(0.13) Estimate

• Benzinga·03/31 11:43

  OS Therapies Completes Filing On Clinical, Biomarker Data From Its Phase 2b Clinical Study Of OST-HER2 To FDA

• Newsfile·03/31 11:40

  OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update

• Dow Jones·03/27 18:27

  OS Therapies Is Maintained at Buy by D. Boral Capital

• Dow Jones·03/27 18:27

  OS Therapies Price Target Maintained With a $20.00/Share by D. Boral Capital

• Benzinga·03/27 10:09

  OS Therapies Engages Four Global Regulators In Q2 2026 Ahead Of Phase 3 Osteosarcoma Trial Enrollment Expected To Begin In Australia

• Newsfile·03/27 10:00

  OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma

• Newsfile·03/25 10:00

  OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma